ADAM12 is A Potential Therapeutic Target Regulated by Hypomethylation in Triple-Negative Breast Cancer
Authors:
- Saioa MendazaSMSaioa Mendaza
- Ane Ulazia-GarmendiaAUAne Ulazia-Garmendia
- Iñaki Monreal-SantestebanIMIñaki Monreal-Santesteban
- Alicia CórdobaACAlicia Córdoba
- Yerani Ruiz de AzúaYAYerani Ruiz de Azúa
- Begoña AguiarBABegoña Aguiar
- Raquel BeloquiRBRaquel Beloqui
- Pedro ArmendárizPAPedro Armendáriz
- Marta ArriolaMAMarta Arriola
- Esperanza Martín-SánchezEMEsperanza Martín-Sánchez
- David Guerrero-SetasDGDavid Guerrero-Setas
Open Access
- 30 January 2020
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (3) , 903
Abstract
Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype and currently lacks any effective targeted therapy. Since epigenetic alterations are a common event in TNBC, DNA methylation profiling can be useful for identifying potential biomarkers and therapeutic targets. Here, genome-wide DNA methylation from eight TNBC and six non-neoplastic tissues was analysed using Illumina Human Methylation 450K BeadChip. Results were validated by pyrosequencing in an independent cohort of 50 TNBC and 24 non-neoplastic samples, where protein expression was also assessed by immunohistochemistry. The functional role of disintegrin and metalloproteinase domain-containing protein 12(ADAM12) in TNBC cell proliferation, migration and drug response was analysed by gene expression silencing with short hairpin RNA. Three genes (Von Willenbrand factor C and Epidermal Growth Factor domain-containing protein (VWCE), tetraspanin-9 (TSPAN9) and ADAM12) were found to be exclusively hypomethylated in TNBC. Furthermore, ADAM12 hypomethylation was associated with a worse outcome in TNBC tissues and was also found in adjacent-to-tumour tissue and, preliminarily, in plasma from TNBC patients. In addition, ADAM12 silencing decreased TNBC cell proliferation and migration and improved doxorubicin sensitivity in TNBC cells. Our results indicate that ADAM12 is a potential therapeutic target and its hypomethylation could be a poor outcome biomarker in TNBC.Keywords
Funding Information
- Interreg (ONCONET, GT 1.2)
- Berrikuntza + Ikerketa + Osasuna Eusko Fundazioa (BIO-11-CM-013)
- La Caixa Foundation (70789)
This publication has 60 references indexed in Scilit:
- Promoter hypermethylation of the tumor-suppressor genes ITIH5, DKK3, and RASSF1A as novel biomarkers for blood-based breast cancer screeningBreast Cancer Research, 2013
- An essential role of metalloprotease-disintegrin ADAM12 in triple-negative breast cancerBreast Cancer Research and Treatment, 2012
- ADAM12 Produced by Tumor Cells Rather than Stromal Cells Accelerates Breast Tumor ProgressionMolecular Cancer Research, 2011
- ADAM12 Transmembrane and Secreted Isoforms Promote Breast Tumor GrowthJournal of Biological Chemistry, 2011
- CpG islands and the regulation of transcriptionGenes & Development, 2011
- Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 StudiesPLOS Medicine, 2010
- Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast CancerJNCI: Journal of the National Cancer Institute, 2009
- A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancerNature Medicine, 2009
- Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast CancerJournal of Clinical Oncology, 2008
- pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐upHistopathology, 1991